Lonza Capacity Update January 2025: Fill/Finish

Discover how Lonza Biologics’ end-to-end Drug Product capabilities support the full lifecycle of biologics, seamlessly integrated with their extensive drug substance network across diverse modalities.

This presentation will showcase the recent expansions at Lonza’s Stein site in Switzerland, which now features a state-of-the-art large-scale commercial manufacturing facility. This expansion is dedicated to biologics filling in various formats, including vials—offered as liquid or lyophilized products—as well as prefilled syringes (PFS) and cartridges, ensuring flexibility for diverse therapeutic needs.

Additionally, the Stein site now boasts cutting-edge capabilities for highly potent Antibody-Drug Conjugate (ADC) manufacturing, complemented by comprehensive development services. These advancements highlight Lonza’s commitment to innovation, quality, and partnership, enabling clients to bring transformative therapies to market with confidence.